NeuroPace (NPCE) Projected to Post Earnings on Tuesday

NeuroPace (NASDAQ:NPCE) is expected to release its earnings data after the market closes on Tuesday, March 4th. Analysts expect NeuroPace to post earnings of ($0.25) per share and revenue of $21.14 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

NeuroPace Price Performance

Shares of NPCE opened at $12.95 on Friday. NeuroPace has a 1 year low of $5.45 and a 1 year high of $16.34. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The company has a market capitalization of $386.53 million, a price-to-earnings ratio of -12.95 and a beta of 2.05. The business has a 50-day moving average of $12.69 and a 200-day moving average of $9.66.

Insider Buying and Selling

In other NeuroPace news, major shareholder Ltd. Kck sold 5,270,845 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Martha Morrell sold 78,334 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $13.72, for a total value of $1,074,742.48. Following the completion of the sale, the insider now directly owns 81,993 shares of the company’s stock, valued at $1,124,943.96. This trade represents a 48.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,352,479 shares of company stock valued at $50,670,217 over the last 90 days. Company insiders own 22.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on NPCE. Wells Fargo & Company raised their price objective on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, January 30th. UBS Group started coverage on NeuroPace in a research note on Tuesday, January 21st. They set a “buy” rating and a $17.00 target price for the company. Finally, JPMorgan Chase & Co. raised their target price on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.80.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.